Prostatic Urethral Lift in Subject With Acute Urinary Retention
Prostatic Urethral Lift in Subject With Acute Urinary Retention
Assess feasibility and safety of the Prostatic Urethra Lift (PUL) procedure in patients with
 acute urinary retention secondary to benign prostatic hyperplasia (BPH).
The study is a multi-centre, prospective evaluation of PUL and retrospective review of
 invasive surgery as potential comparator. The study is intended to be conducted at up to 5
 different centres in the United Kingdom to enrol up to 50 subjects. Subject follow-up visits
 are at post-procedure, 6 weeks, 3 months, 6 months and 12 months.
UroLift System Procedure Arm

 Inclusion Criteria:

 1. Male gender

 2. Diagnosis of symptomatic BPH

 3. Age ≥ 50 years

 4. Prostate volume ≤ 100 cc per ultrasound (US)

 5. Acute urinary retention with at least one failed trial without catheter (TWOC) while
 on alpha blocker

 Exclusion Criteria:

 1. An obstructive or protruding median lobe of the prostate

 2. Previous BPH surgical procedure

 3. Previous pelvic surgery

 4. Urethral conditions that prevents insertion and delivery of device system into bladder

 5. Retention volume of >1500 mL

 6. Has not had prostate cancer excluded

 7. History of prostate or bladder cancer

 8. Biopsy of the prostate within the 6 weeks prior to Index Procedure

 9. History of neurogenic or atonic bladder

 10. Acute or chronic renal failure

 11. Known coagulopathies or subject on anticoagulants within 3 days of index procedure
 (excluding up to 100mg ASA)

 12. Known bladder stones within the prior 3 months or treatment within 12 months

 13. Prostatitis requiring treatment (antibiotics) within the last year

 14. Other co-morbidities that could impact the study results

 -  severe cardiac arrhythmias uncontrolled by medications or pacemaker

 -  congestive heart failure New York Heart Association (NYHA) III or IV

 -  history of uncontrolled diabetes mellitus

 -  significant respiratory disease in which hospitalisation may be required

 -  known immunosuppression (i.e. AIDS, post-transplant, undergoing chemotherapy)

 15. Life expectancy estimated to be less than 5 years

 16. Desire to maintain fertility post procedure

 17. Unable or unwilling to complete all required questionnaires and follow up assessments

 18. Unable or unwilling to sign informed consent form

 19. Currently enroled in any other clinical research trial that has not completed the
 primary endpoint